Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Femasys Inc. SEC filings document the company’s women’s health medical-device business, Nasdaq-listed common stock, operating results, and product-related corporate updates. Recent 8-K filings furnish quarterly and annual financial results and disclose material events tied to executive appointments, employment agreements, financing instruments, and listing compliance matters.
Proxy materials cover annual and special stockholder meetings, board elections and governance matters, reverse stock split authorization, and share-issuance approvals linked to capital-structure provisions. Other filings describe senior secured convertible notes, warrant amendments, Nasdaq minimum bid price compliance, and the company’s emerging growth company reporting status.
Femasys Inc. held its Annual Meeting of Stockholders, where holders of 1,487,447 shares of common stock, representing approximately 49.26% of shares eligible to vote, were present in person virtually or by proxy. All vote totals were adjusted for the 1-for-20 reverse stock split effective June 5, 2026.
Stockholders elected Charles Larsen and Kenneth Eichenbaum as Class II directors for three-year terms ending at the 2029 annual meeting, each receiving substantially more votes for than against. Stockholders also ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026 by a wide margin.
Femasys Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market. The company achieved this after a 1-for-20 reverse stock split of its common stock became effective on June 5, 2026, and its closing bid price stayed at or above $1.00 for 10 consecutive business days. Nasdaq has confirmed that the compliance matter is now closed. Femasys continues to focus on commercializing its fertility and non-surgical permanent birth control products and advancing clinical development of FemBloc.
Femasys Inc. implemented a 1-for-20 reverse stock split of its common stock, effective at 8:40 a.m. Eastern Time on June 5, 2026. Every 20 issued and outstanding shares were automatically combined into one share, with no change to the $0.001 par value.
The split applies to all outstanding shares and proportionately adjusts stock options, RSUs and warrants by reducing underlying share counts and increasing exercise prices. Shares reserved under the equity compensation plan were also reduced proportionately. Fractional shares will not be issued and will instead be rounded up to the next whole share at the DTC participant level.
The reverse split affects all stockholders proportionately, so percentage ownership is unchanged apart from minor effects from fractional share rounding. Femasys common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis on June 8, 2026, under a new CUSIP number 31447E 204.
Femasys Inc. will implement a 1-for-20 reverse stock split of its common stock, effective at 4:30 p.m. Eastern Time on June 5, 2026. Each 20 pre-split shares will be combined into one share, and no cash will be paid for fractional shares, which will be rounded up to the next whole share at the DTC participant level.
The split-adjusted shares will begin trading on June 8, 2026 under the same ticker symbol “FEMY,” but with a new CUSIP number, 31447E 204. Stockholders of record will receive updated account details from the company’s transfer agent, Broadridge Investor Communication Solutions, Inc.
Femasys Inc. filed an 8-K to share an updated corporate presentation outlining its women’s reproductive health portfolio and growth strategy. The slide deck highlights FDA-cleared and internationally approved products, including FemaSeed for in-office fertility treatment and FemBloc, a non-surgical permanent birth control now in a U.S. pivotal trial.
The company emphasizes a large unmet fertility and contraception market, noting record-low U.S. fertility rates and limited innovation in first-line care. It presents clinical data showing FemaSeed achieved about double the pregnancy rate of intrauterine insemination in a trial, and early FemBloc data showing a 0% pregnancy rate versus historical surgical controls, along with favorable in-office economics for OB/GYN practices.
Femasys Inc. reported net income of $846,100 for the quarter ended March 31, 2026, compared with a net loss a year earlier. Sales rose to $424,889, driven mainly by FemVue, while operating expenses were $4,489,816, reflecting higher sales and marketing but sharply lower research and development spending.
The company’s profit was primarily due to $5,069,633 of other income, including large non‑cash gains from changes in the fair value of its convertible note conversion option and warrant liabilities. Cash and cash equivalents fell to $5,386,041 after $4,143,508 of cash used in operating activities, and the accumulated deficit reached $144,980,044.
Management states that existing cash, expected product revenue and current facilities are only sufficient to fund operations into the third quarter of 2026, and that substantial doubt exists about Femasys’ ability to continue as a going concern without additional financing. The company highlights significant potential dilution from outstanding convertible notes and multiple warrant series as it pursues commercialization of its women’s health portfolio and the pivotal FemBloc trial.
Femasys Inc. reported financial results for the quarter ended March 31, 2026 and provided a corporate update. Sales were $424,889, up from $341,264 a year earlier, while loss from operations narrowed to $4,223,533 from $5,460,607.
Benefiting from fair value adjustments to its conversion option and warrant liabilities, the company recorded net income of $846,100, versus a prior-year net loss of $5,896,839. Cash and cash equivalents were $5,386,041 as of March 31, 2026, and management believes current cash resources can fund operations into the third quarter of 2026.
Commercially, Femasys is accelerating rollout of FemaSeed intratubal insemination with its FemSperm product family, enabling in-office fertility care. Clinically, it has initiated patient enrollment in the FINALE pivotal trial for FemBloc non-surgical permanent birth control, a key step toward potential U.S. FDA approval.
Femasys Inc. will hold its 2026 Annual Meeting of Stockholders on June 24, 2026 at 9:00 a.m. Eastern in Suwanee, Georgia. Stockholders of record at the close of business on April 27, 2026 may vote.
Investors are asked to elect two Class II directors, Charles Larsen and Kenneth Eichenbaum, to three-year terms and to ratify KPMG LLP as independent auditor for the year ending December 31, 2026. The proxy describes board independence, committee structure, director compensation, major stockholders, executive pay and employment agreements, a Dodd-Frank–compliant clawback policy, and procedures for submitting proposals for the 2027 annual meeting.
Femasys Inc. held a Special Meeting where stockholders approved two key measures. First, they authorized the board to implement a reverse stock split of the common stock at any ratio between 1-for-2 and 1-for-25 at any time before May 1, 2027, giving the board flexibility to reduce the number of shares outstanding. Second, they approved, for Nasdaq rule purposes, issuing more than 19.99% of the company’s common stock upon conversion of senior secured convertible notes and exercise of multiple warrant series if anti-dilution or price adjustments push conversion or exercise prices below the Nasdaq Minimum Price.